Figure 5 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

Le résumé fourni par la source

PELP1-KD or SMIP34 treatment suppresses HCC xenograft tumor growth in vivo. Hep3B–control and Hep3B–PELP1-KD model cells were injected subcutaneously into female (A, D, and G) or male SCID mice (B, E, and H). Tumor volumes were assessed at 3 to 5 days of intervals. Tumor volume (A and B), tumor weights (D and E), and IHC analyses of Ki67 and PELP1 (G and H) for tumors are shown. Hep3B xenograft tumor fragments measuring 2 to 3 mm3 were implanted subcutaneously , and following tumor establishment (∼200 mm3), the mice were randomly assigned to receive either vehicle (control) or SMIP34 (20 mg/kg body weight) 5 days a week through i.p. injection (n = 5). Tumor volume (C), tumor weights (F) and IHC analyses of Ki67 and PELP1 (I) for tumors are shown. Scale bar, 100 μm. Data are represented as the mean ± SEM. P values are calculated using Student t test and two-way ANOVA, *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Cont sh (Control short hairpin).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.